- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02465775
Fat Reduction in the Flanks Area vs. Control
Clinical Study to Evaluate the Performance of the UltraShape Device for Fat Reduction Treatment in the Flanks Area vs. Control
Prospective, blinded, one arm, baseline-controlled clinical study for the evaluation the performance of the UltraShape treatment for non-invasive fat reduction by compare control and treated flanks.
Study subjects will undergo UltraShape treatments on one randomized flank using the U-Sculpt/VDF Transducer. The second flank will not be treated (control). Both flanks (treated and control) will be compared to baseline, as well as, one to each other
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, baseline and blinded controlled, comparison, clinical study showing the performance and safety of the UltraShape treatment for non-invasive fat reduction at the flanks area comparing improvement observed in treated versus control flanks.
Up to 60 Healthy subjects in up to 4 investigational sites will be enrolled in this study. All subjects will undergo an assessment of their general health. During the treatment period, subject's fat thickness will be measured on both flanks. Three successive bi-weekly (two weeks interval) UltraShape treatments will be performed on one randomized flank, while the second flank will not be treated and served as a control.
The study subjects will undergo UltraShape treatments on one flank using the U-Sculpt /VDF Transducer, the treated flank will remain steady along the study and will be comparing to the baseline and to the controlled flank Three follow-up visits will be conducted as follows: 4 weeks (4wk FU), 8 weeks (8wk FU) and 16 weeks (16wk FU) post last treatment (Tx.3).
Subject's fat thickness will be measured on both flanks in the measurements points using caliper at each visit (at treatment visits, prior to treatment). Ultrasound measurements will be taken at each visit, except for the second treatment visit, on each flank. Investigator satisfaction will be assessed at all FU visits. In addition, subject questionnaires will be completed at each follow-up visit. Photographs of the front, right, left and back view of each flank will be performed under visible light conditions at each study visit.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Weiss, MD
- Phone Number: 410-666-3960
Study Locations
-
-
Louisiana
-
Metairie, Louisiana, United States, 70006
- Recruiting
- Coleman Center For Cosmetic Dermatologic Surgery
-
Contact:
- Karyn Fortier
- Phone Number: 504-455-3180
- Email: drcolemanresearch@gmail.com
-
Principal Investigator:
- William P Coleman, M.D.
-
-
Maryland
-
Hunt Valley, Maryland, United States, 21030
- Recruiting
- Maryland Laser, Skin, & Vein Institute, LLC
-
Contact:
- Cristi Myers
- Phone Number: 410-666-3960
- Email: info@mdlsv.com
-
Principal Investigator:
- Robert A Weiss, M.D.
-
-
Tennessee
-
Nashville, Tennessee, United States, 37215
- Recruiting
- Gold Skincare
-
Contact:
- Brynne Thompson
- Phone Number: 615-383-9660
- Email: BThompson@tnclinicalresearch.com
-
Principal Investigator:
- Michael Gold, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent to participate in the study.
- Female and male subjects, between 18 to 60 years of age at the time of enrolment
- Fitzpatrick Skin Type I to VI.
- Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper).
- BMI interval: BMI between 22 to 30 (normal to overweight, but not obese).
- If female, not pregnant or lactating, must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
- In addition, negative urine pregnancy test as tested before each treatment and at the last follow-up visit for women with child-bearing potential (e.g. not menopause).
- General good health confirmed by medical history and skin examination of the treated area.
- Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
- Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
- Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations
Exclusion Criteria:
- History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism
- Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
- Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
- Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
- Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone
- Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction
- Previous body contouring procedures in the treatment area within 12 months
- History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
- Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
- Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
- Very poor skin quality (i.e., severe laxity)
- Abdominal wall diastasis or hernia on physical examination
- Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
- Obesity (BMI above 30)
- Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study
- Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
- Fat thickness lower than 2.5 cm after strapping at the treated area.
- Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s).
- As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UltraShape treatment in all subjects
UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
|
Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
efficacy of flank fat reduction vs. control
Time Frame: up to 16 weeks after treatment
|
Evaluate the efficacy of UltraShape treatments with the U-sculpt/VDF Transducer for flanks fat reduction as assessed by comparing the change during the study on the treated flank area and compare to the change observed on the un-treated (control) flank
|
up to 16 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fat thickness reduction on the treated flank
Time Frame: 4, 8 and 16 weeks
|
measured by caliper and by Ultrasound device
|
4, 8 and 16 weeks
|
Investigator satisfaction assessment
Time Frame: 4, 8 and 16 weeks
|
5-Point Likert Scale
|
4, 8 and 16 weeks
|
Subject satisfaction assessment
Time Frame: 4, 8 and 16 weeks
|
Subjects will answer the questionnaire
|
4, 8 and 16 weeks
|
pain assessment
Time Frame: day 0, 2 weeks and 4 weeks
|
NSR scale
|
day 0, 2 weeks and 4 weeks
|
Safety of flank fat reduction
Time Frame: up to 20 weeks after treatment
|
Evaluate the safety of the treatment with the UltraShape device using the U-Sculpt/VDF Transducer for flanks treatment area
|
up to 20 weeks after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Weiss, MD, 54 Scot Adams Road, Hunt Valley Baltimore USA
- Principal Investigator: William P. Colem, MD, Coleman Center For Cosmetic Dermatologic Surgery
Publications and helpful links
General Publications
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- DHF18361
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flanks Fat Reduction vs. Control
-
Syneron MedicalSuspendedUnwanted Flanks Fat
-
Zeltiq AestheticsCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffAllerganCompletedFat ReductionUnited States
-
University of BaghdadEman Hammad HafithCompleted
-
AllerganCompletedNon-invasive Fat ReductionAustralia, Canada, Singapore, United Kingdom
-
Zeltiq AestheticsCompleted
-
AllerganCompletedNon-invasive Fat ReductionUnited States, France, Singapore, Sweden, Germany
-
Zeltiq AestheticsCompletedFat Reduction in the AbdomenCanada
-
Zeltiq AestheticsCompletedFat Reduction in the Upper ArmCanada
-
BTL Industries Ltd.CompletedThighs Circumferential Reduction | Subcutaneous Fat Cell Disruption
Clinical Trials on UltraShape treatment
-
Syneron MedicalSuspendedUnwanted Flanks Fat
-
Syneron MedicalCompleted
-
Syneron CandelaUnknown
-
Syneron MedicalUnknownExcess Abdominal FatUnited States
-
Syneron MedicalWithdrawn
-
UltraShapeUnknownReduction in Abdominal CircumferenceIsrael
-
Syneron MedicalCompletedCircumference ReductionUnited States
-
Syneron MedicalUnknownUnwanted Thigh FatUnited States
-
Syneron MedicalCompleted
-
Syneron MedicalWithdrawnGynecomastia | Male Breast Enlargement